Switching Tenofovir/Emtricitabine plus Lopinavir/r to Raltegravir plus Darunavir/r in Patients with Suppressed Viral Load Did Not Result in Improvement of Renal Function but Could Sustain Viral Suppression: A Randomized Multicenter Trial

BACKGROUND: Whether tenofovir nephrotoxicity is reversible after its withdrawal is unknown. Furthermore, there are no data on the viral efficacy of raltegravir (RAL) plus ritonavir-boosted Darunavir (DRV/r) in patients with suppressed viral load. METHODS: This multicenter, randomized trial compared...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishijima, Takeshi, Gatanaga, Hiroyuki, Shimbo, Takuro, Komatsu, Hirokazu, Endo, Tomoyuki, Horiba, Masahide, Koga, Michiko, Naito, Toshio, Itoda, Ichiro, Tei, Masanori, Fujii, Teruhisa, Takada, Kiyonori, Yamamoto, Masahiro, Miyakawa, Toshikazu, Tanabe, Yoshinari, Mitsuya, Hiroaki, Oka, Shinichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738570/
https://www.ncbi.nlm.nih.gov/pubmed/23951362
http://dx.doi.org/10.1371/journal.pone.0073639

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738570/
https://www.ncbi.nlm.nih.gov/pubmed/23951362
http://dx.doi.org/10.1371/journal.pone.0073639

Ejemplares similares